On November 3, 2026, Morgan Stanley acquired 932,097 shares of PHARMARON (03759) (H shares) arising from an increase in shares over which it may exercise a right to rehypothecate or dispose of, with no SEHK on-exchange trade involved and thus not a direct secondary-market dealing.
Prior to the acquisition, Morgan Stanley’s long position in PHARMARON was 17.56 million shares, representing 4.9%; following the acquisition, the holding changed to 18.49 million shares, with the long position ratio rising to 5.13%.
Source: Hong Kong Exchanges and Clearing Limited.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments